Czech producer of generic medications Zentiva is poised for a change in ownership as Advent has agreed to sell the company to GTCR, another private equity investor with a focus on the healthcare sector. The sale, initially reported by the Financial Times according to Reuters, is estimated to be worth €4.1bn ($4.8bn). Zentiva's operations span the development, production and distribution of medicines in more than 30 countries across Europe and beyond. The company has four completely-owned manufacturing f ...